Brexit and British Biotech; A Second Look from ESOF
In the wake of my recent post on the potential impact of Brexit on British Biotechnology, I am fortunate to […]
Brexit and British Biotech; A Second Look from ESOF Read Post »
In the wake of my recent post on the potential impact of Brexit on British Biotechnology, I am fortunate to […]
Brexit and British Biotech; A Second Look from ESOF Read Post »
I have a tool that can be used to measure the impact of Brexit on biotechnology in the United Kingdom.
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
DrugPatentWatch offers PDF copies of the FDA Orange Book dating back to 1980. The Food and Administration (FDA) Orange Book, or Approved
On Thursday June 9th from 10:30 to 11:30pm in Room 124 North Mike May and I will be going over the
Get your Worldview on — Measuring Global Biotechnology at #BIO2016 Read Post »
My book signing sold out, but do not despair — you can still get a signed copy. Signed copies of Building
I will be signing my textbook Building Biotechnology, and other books, in the BIO bookstore on Wednesday June 8th from 12:30 pm
This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s
Biotech in Countries Starting with “I” – Part 10: India Read Post »
This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a
Biosimilar Naming: Distinguishable or Disingenuous? Read Post »
[slideshare id=61425574&doc=whendodrugpatentsexpire-160427163211] When do drug patents expire, and when can generic drugs launch? An overview of patents, non-patent regulatory exclusivities,
When do Drug Patents Expire, and When Can Generic Drugs Launch? Read Post »
Get new actionable insights and updates from BiotechBlog